The Paradigm Shift in Chronic Hepatitis B Management
On January 7, 2026, the landscape of hepatology reached a historic turning point. GlaxoSmithKline (GSK) announced that its investigational antisense oligonucleotide (ASO), Bepirovirsen, successfully achieved its primary endpoints in two landmark Phase III clinical trials: B-Well 1 and B-Well 2. This breakthrough represents more than just a successful clinical trial; it signals a fundamental shift in the treatment paradigm for Chronic Hepatitis B (CHB), moving from the current model of lifelong viral suppression toward a finite, curative therapeutic approach.
For the estimated 250 to 300 million individuals globally living with CHB, the prospect of functional cure—defined as the sustained loss of Hepatitis B surface antigen (HBsAg) and undetectable HBV DNA after the cessation of therapy—has long been the ultimate clinical goal. Historically, this goal was rarely achieved with existing standard-of-care treatments. The B-Well trial results suggest that this goal is now within clinical reach for a significant portion of the patient population.
